Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Equivalents (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash & Equivalents for 4 consecutive years, with $197.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 57.7% to $197.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $197.1 million, a 57.7% increase, with the full-year FY2025 number at $197.1 million, up 57.7% from a year prior.
  • Cash & Equivalents was $197.1 million for Q4 2025 at Day One Biopharmaceuticals, up from $43.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $422.8 million in Q3 2024 to a low of $33.4 million in Q1 2025.
  • A 4-year average of $183.5 million and a median of $193.1 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 448.82% in 2024, then crashed 89.76% in 2025.
  • Day One Biopharmaceuticals' Cash & Equivalents stood at $85.3 million in 2022, then soared by 170.68% to $230.8 million in 2023, then crashed by 45.85% to $125.0 million in 2024, then soared by 57.7% to $197.1 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Cash & Equivalents are $197.1 million (Q4 2025), $43.3 million (Q3 2025), and $35.6 million (Q2 2025).